已确诊类风湿关节炎的超声滑膜炎及临床-超声表型均不能预测靶向治疗反应
该观察性队列研究连续纳入200例开始靶向治疗的已确诊类风湿关节炎患者,在基线和治疗6个月后行临床评估、38关节肌肉骨骼超声及患者报告结局,用潜类别分析识别出3个炎症程度不同的疾病聚类,多因素回归显示基线超声滑膜炎和炎症聚类均不能预测EULAR反应。
要点
- 连续纳入200例已确诊类风湿关节炎起始靶向治疗患者,基线及6个月行38关节超声评估。
- 潜类别分析识别出3个由低到高炎症程度的聚类,关节能量多普勒中位数分别为2、9、29.5。
- 基线有滑膜炎者EULAR反应的相对风险比为1.05(95%CI 0.38, 2.93),未达统计学显著。
核心结论
- 这是首个采用38关节肌肉骨骼超声识别类风湿关节炎表型的研究,基线滑膜炎和炎症聚类均未预测临床反应。
- 作者认为需要从机制上理解靶向治疗反应与无反应,临床试验仍需纳入这些人群。
研究设计与样本
- 观察性队列研究,连续纳入200例已确诊类风湿关节炎并开始靶向治疗的患者。
- 基线和治疗6个月后行临床评估、38关节肌肉骨骼超声(灰阶和能量多普勒评估滑膜炎/腱鞘炎)及患者报告结局。
- 采用潜类别分析识别临床和超声变量的疾病聚类,用多项逻辑回归模型判断基线滑膜炎和/或聚类是否预测EULAR反应。
主要发现
- 识别出3个由低到高炎症程度的聚类,关节能量多普勒总分中位数(IQR)在聚类1为2(0-4)、聚类2为9(6-13)、聚类3为29.5(21-45)。
- 健康评估问卷与疾病活动度相关,DAS-P评分分布在聚类间不同(P = 0.001),但中位数相同;其他患者报告结局无差异。
- 6个月时,基线有滑膜炎者相比无滑膜炎者的EULAR反应相对风险比为1.05(95%CI 0.38, 2.93)。
- 相比最低炎症聚类[1],聚类2的EULAR反应相对风险比为1.50(95%CI 0.61, 3.70),聚类3为1.24(95%CI 0.43, 3.60)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify patient sub-phenotypes using clinical and imaging measures in established rheumatoid arthritis (RA) and to establish if baseline ultrasound synovitis and/or baseline patient sub-phenotypes predicts response to targeted therapy (TT). METHODS: This was an observational cohort study of consecutively recruited patients with established RA starting TT. Participants received clinical assessment, 38-joint musculoskeletal ultrasound (MSUS), measuring grey scale and power Doppler (PD) synovitis/tenosynovitis, and patient reported outcomes (PRO), prior to and 6 months after treatment. Latent profile analysis of the clinical and MSUS variables identified disease clusters, and multinomial logistic regression models determined whether these and/or baseline synovitis predicted EULAR response. RESULTS: Of 200 recruited patients, three clusters, low to high inflammatory, were identified with median (IQR) total joint PD 2 (0-4) in cluster 1, 9 (6-13) in cluster 2 and 29.5 (21-45) in cluster 3. A health assessment questionnaire correlated with disease activity, and DAS-P score distributions differed between clusters (P = 0.001) but with identical medians. Other PROs did not differ. At 6 months relative risk ratio of EULAR response in those with baseline synovitis compared with those without was 1.05 (95% CI: 0.38, 2.93) and response compared with the lowest inflammatory cluster [1] was 1.50 (95% CI: 0.61, 3.70) for cluster 2 and 1.24 (95% CI: 0.43, 3.60) for cluster 3. CONCLUSION: This is the first study to identify RA phenotypes employing 38-joint MSUS. Strikingly, neither baseline synovitis nor inflammatory cluster predicted clinical response. Mechanistic understanding of TT response/non-response is needed and clinical trials need to still capture all these populations.
引用
- Fitton J, Melville A, Di Matteo A, et al. Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapy. Rheumatology (Oxford). 2025. PMID: 40568845. doi:10.1093/rheumatology/keaf315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。